These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20652456)

  • 21. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
    Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of pre-treatment 18F-FAMT PET to predict patient survival in squamous cell carcinoma of the esophagus treated by curative surgery.
    Sohda M; Sakai M; Honjyo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Yokobori T; Miyazaki T; Fukuchi M; Higuchi T; Tsushima Y; Kuwano H
    Anticancer Res; 2014 Jul; 34(7):3623-8. PubMed ID: 24982378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of cervical metastases with (11)C-tyrosine PET in patients with squamous cell carcinoma of the oral cavity or oropharynx: A comparison with (18)F-FDG PET.
    Krabbe CA; van der Werff-Regelink G; Pruim J; van der Wal JE; Roodenburg JL
    Head Neck; 2010 Mar; 32(3):368-74. PubMed ID: 19626632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.
    Zhao Z; Yoshida Y; Kurokawa T; Kiyono Y; Mori T; Okazawa H
    J Nucl Med; 2013 Apr; 54(4):499-506. PubMed ID: 23471314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advantages of L-3-[(18)F] fluoro-alpha-methyl tyrosine over 2-[(18)F]-fluoro-2-deoxyglucose in detecting liver metastasis during positron emission tomography scan.
    Kodaira S; Nakajima T; Arisaka Y; Tokue A; Higuchi T; Tsushima Y
    Springerplus; 2016; 5():618. PubMed ID: 27330884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship Between Tumor Immune Markers and Fluorine-18-α-Methyltyrosine ([
    Shimizu K; Kaira K; Higuchi T; Hisada T; Yokobori T; Oyama T; Asao T; Tsushima Y; Shirabe K
    Mol Imaging Biol; 2020 Aug; 22(4):1078-1086. PubMed ID: 31792836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study.
    Tian M; Zhang H; Nakasone Y; Mogi K; Endo K
    Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):5-12. PubMed ID: 14551748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preparation and biological evaluation of 3-[(76)Br]bromo-α-methyl-L-tyrosine, a novel tyrosine analog for positron emission tomography imaging of tumors.
    Ohshima Y; Hanaoka H; Watanabe S; Sugo Y; Watanabe S; Tominaga H; Oriuchi N; Endo K; Ishioka NS
    Nucl Med Biol; 2011 Aug; 38(6):857-65. PubMed ID: 21843782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological evaluation of 3-[(18)F]fluoro-α-methyl-D-tyrosine (D-[(18)F]FAMT) as a novel amino acid tracer for positron emission tomography.
    Ohshima Y; Hanaoka H; Tominaga H; Kanai Y; Kaira K; Yamaguchi A; Nagamori S; Oriuchi N; Tsushima Y; Endo K; Ishioka NS
    Ann Nucl Med; 2013 May; 27(4):314-24. PubMed ID: 23337966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma.
    Kunkel M; Reichert TE; Benz P; Lehr HA; Jeong JH; Wieand S; Bartenstein P; Wagner W; Whiteside TL
    Cancer; 2003 Feb; 97(4):1015-24. PubMed ID: 12569601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of 18F-α-Methyltyrosine PET for Therapeutic Monitoring of Patients with Advanced Lung Cancer.
    Kaira K; Higuchi T; Sunaga N; Arisaka Y; Hisada T; Tominaga H; Oriuchi N; Asao T; Tsushima Y; Yamada M
    Anticancer Res; 2016 Dec; 36(12):6481-6490. PubMed ID: 27919971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study.
    Kaira K; Oriuchi N; Otani Y; Shimizu K; Tanaka S; Imai H; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Dobashi K; Kanai Y; Endou H; Nakajima T; Endo K; Mori M
    Clin Cancer Res; 2007 Nov; 13(21):6369-78. PubMed ID: 17975149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transport of 3-fluoro-L-α-methyl-tyrosine (FAMT) by organic ion transporters explains renal background in [(18)F]FAMT positron emission tomography.
    Wei L; Tominaga H; Ohgaki R; Wiriyasermkul P; Hagiwara K; Okuda S; Kaira K; Kato Y; Oriuchi N; Nagamori S; Kanai Y
    J Pharmacol Sci; 2016 Feb; 130(2):101-9. PubMed ID: 26887331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck.
    Ng SH; Yen TC; Chang JT; Chan SC; Ko SF; Wang HM; Lee LY; Kang CJ; Wong AM; Liao CT
    J Clin Oncol; 2006 Sep; 24(27):4371-6. PubMed ID: 16983105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [18F]fluoro-2-deoxyglucose-positron emission tomography for the assessment of histopathological response after preoperative chemoradiotherapy in advanced oral squamous cell carcinoma.
    Shimomura H; Sasahira T; Yamanaka Y; Kurihara M; Imai Y; Tamaki S; Yamakawa N; Shirone N; Hasegawa M; Kuniyasu H; Kirita T
    Int J Clin Oncol; 2015 Apr; 20(2):308-16. PubMed ID: 24942501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-FAMT PET Is Useful to Distinguish between Specific Uptake and Nonspecific Uptake Compared to 18F-Flourodeoxyglucose Position Emission Tomography in Esophageal Cancer Patients.
    Sohda M; Miyazaki T; Honjyo H; Hara K; Ozawa D; Sakai M; Yokobori T; Higuchi T; Tsushima Y; Kuwano H
    Dig Surg; 2018; 35(5):383-388. PubMed ID: 29130979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of recurrent oral squamous cell carcinoma by [18F]-2-fluorodeoxyglucose-positron emission tomography: implications for prognosis and patient management.
    Kunkel M; Förster GJ; Reichert TE; Jeong JH; Benz P; Bartenstein P; Wagner W; Whiteside TL
    Cancer; 2003 Nov; 98(10):2257-65. PubMed ID: 14601097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of
    Mitamura K; Yamamoto Y; Norikane T; Hatakeyama T; Okada M; Nishiyama Y
    Ann Nucl Med; 2018 Nov; 32(9):627-633. PubMed ID: 30032455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?
    Buck AC; Schirrmeister HH; Guhlmann CA; Diederichs CG; Shen C; Buchmann I; Kotzerke J; Birk D; Mattfeldt T; Reske SN
    J Nucl Med; 2001 May; 42(5):721-5. PubMed ID: 11337566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.